Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Jazz Pharmaceuticals (JAZZ - Analyst Report) recently initiated a study on Erwinaze (asparaginase Erwinia chrysanthemi) for the treatment of patients suffering from acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Erwinaze offers an intravenous and alternative method of administration for the treatment of ALL. Jazz Pharma expects to enroll around 25 patients with ALL in the US and Canada for the study. The patients must have a documented Grade 2 or higher hypersensitivity reaction to native or pegylated E. coli asparaginase and are yet to complete their full courses of prescribed asparaginase therapy.

Jazz Pharma expects preliminary pharmacokinetic data from the study in the second half of 2013.

We note that Jazz Pharma added Erwinaze to its portfolio after its EUSA Pharma acquisition. The $680 million EUSA Pharma acquisition was closed in June this year. Jazz Pharma will be paying an additional $50 million if net sales from Erwinaze exceed or equal $124.5 million in the US in 2013.

Jazz Pharma reported Erwinaze sales of $31.7 million in the third quarter this year. Notably, in November 2011, Erwinaze was approved by the US Food and Drug Administration for the treatment of ALL, under a biological license application. The drug is also being sold under marketing authorizations, named patient programs, temporary use authorizations or similar authorizations in the EU and other countries.

We note that players like ARIAD Pharmaceuticals (ARIA - Snapshot Report) are looking to enter the ALL market.

Currently, we have a Neutral recommendation on Jazz Pharmaceuticals. The stock carries a Zacks #4 Rank (Sell).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%